Disetronic shares soar nearly 70% after flotation:
This article was originally published in Clinica
Executive Summary
The newly-floated shares of Swiss company Disetronic rose nearly 70% in the first days of trading on the Zurich stock exchange. The manufacturer of portable drug delivery systems priced its initial public offering at SwFr 1,350 ($1,090) a share and on June 20th, the third day of trading, the shares stood at SwFr 2,250. This values the company, based in Burgdorf, at around SwFr 500 million. The flotation raised SwFr 72 million for Disetronic from the sale of 50,000 newly issued shares. The remaining 22,000 shares were sold by existing stockholders. With a voting stake of 63%, CEO Willy Michel remains in control of the company. After the flotation, shares representing 14% of the vote and 29% of the capital are publicly owned.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.